In its latest quarterly update, YD Bio USA formed a Master Strategic Alliance with YC Biotech to build a dual-core regulatory platform facilitating FDA submissions. Concurrently, YD Bio is advancing clinical development of its Limbal Stem Cell (LSC) exosome therapies targeting ophthalmic conditions, backed by a reusable FDA regulatory framework. The company is also progressing a pending acquisition of Safe Save Medical Cell Sciences & Technology, broadening its immunotherapy portfolio. These initiatives underpin YD Bio's strategy to scale through multi-segment healthcare regulated markets, although recurring operating losses and financing needs remain material risks.